2,031.50
+4.34%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Wockhardt
Its shares trade on NSE under the ticker WOCKPHARMA.NS. It has been listed since 25 February 1994. In the fiscal year to 31 March 2026, it reported revenue of ₹33.73bn and net income of ₹2.13bn. At that date it held total assets of ₹86.15bn and shareholders' equity of ₹49.40bn.
Wockhardt Ltd. engages in the pharmaceutical business. The company is headquartered in Mumbai, Maharashtra. The firm's businesses include manufacture and marketing of pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs) and vaccines. The company manufactures a range of dosage forms, including sterile injectables and lyophilized products. The firm offers products in therapeutic areas of dermatology, cosmeceuticals, oncology, medical nutrition, osteoarthritis, pain management, nephrology, cough therapy and diabetology. The Company’s products across India includes Citawok, Citawok Forte, Citawok Plus, CONSEGNA 30/70 U-200 CART, CONSEGNA R U-200 CART, DARBOTIN PFS, DECDAN, DECDAN B, DECDAN B Injection, DECDAN LITE CREAM, Emrok, Emrok O, Erliso, FOSCHEK-S, Gabawok NT, GLARITUS CART, GLARITUS DISPO, Glimaday, INOGLA, Livatira, GLARITUS CART and VAL 450. The company has manufacturing and research facilities in India, United States of America and the United Kingdom and a manufacturing facility in Ireland.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 25 Feb 1994
- Employees
- 2,740
- Website
- wockhardt.com ↗
Leadership
Pay as last reported
- Dr. Habil Fakhruddin KhorakiwalaExecutive Chairman of the Board, since 1999₹36.5m
- Mr. Deepak MadnaniChief Financial Officer, since 2022₹9.8m
- Ms. Rashmi MamturaCompliance Officer, Company Secretary
- Dr. Murtaza Habil KhorakiwalaManaging Director, Executive Director, since 2009₹21.2m
- Dr. Huzaifa Habil KhorakiwalaExecutive Director, since 2009₹21.2m
- Ms. Zahabiya Habil KhorakiwalaNon-Executive Non- Independent Director₹300,000
- Ms. Amelia FernandesNon-Executive Independent Director₹1.0m
- Mr. Akhilesh GuptaNon-Executive Independent Director₹1.1m
- Mr. Vinesh JairathNon-Executive Independent Director₹1.7m
- Amb. Ahmad JavedNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 83
- Environment
- 82
- Social
- 99
- Governance
- 68
- Direct emissions (scope 1)
- 11,404.22 t
- Energy emissions (scope 2)
- 61,358.41 t
- Value chain emissions (scope 3)
- 67,589.94 t
- Women in the workforce
- 7.5784%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Wockhardt Ltd. manufactures pharmaceutical formulations and APIs in Mumbai, India.
- The company offers products like Citawok and DECDAN across India.
- Wockhardt has manufacturing facilities in the USA, UK, and Ireland for global reach.
Weaknesses
- Wockhardt employs 2,740 full-time employees in Mumbai, Maharashtra.
- The company's business is limited to pharmaceuticals in the Health Care sector.
- Wockhardt's products include dermatology and oncology treatments in India.
Opportunities
- Wockhardt's manufacturing facilities in the USA and UK support international expansion.
- The company's focus on oncology and medical nutrition presents growth opportunities.
- Wockhardt's product portfolio includes sterile injectables and lyophilized products.
Threats
- Wockhardt's business is concentrated in the Health Care sector, increasing market vulnerability.
- The company's reliance on India for manufacturing may pose supply chain risks.
- Wockhardt's products like Citawok and DECDAN face competition in the Indian market.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.